
Приятно сообщать хорошие известия, особенно в такой замечательный день, Ваш день, дорогие женщины. Позвольте пожелать Вам преодолеть проблемы, приведшие Вас сюда, удачи Вам и счастья.
Ну, а теперь о хороших новостях. Совершенно случайно именно сегодня прочел вот эту статью http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3535097/ . Статья длинная, на английском языке и я не предлагаю Вам садится ее читать, особенно в такой день. Но меня она взволновала до крайности. Объяснимся. Речь в ней идет о куркуме. Несколько лет назад я поместил здесь пост “куркума-оружие главного калибра”, где цель, разумеется, рак. Основываясь на многочисленных научных публикациях, я даже имел смелость предположить, что если удасться решить проблему крайне низкой усвояемости куркумы, то проблема рака,как таковая, во многом перестанет существовать. Почему. Куркума это такое природное соединение, которое одновременно воздействует практически на все pathways или пути развития или пути метаболизма раковой опухоли. На рисунки, который я позаимствовал из исследовательской работы(который у меня там, почему то не воспроизвелся) показаны все 16 pathways, замечу, что даже если останется только 1 из 16 путей, опухоль не перестанет развиваться.
Ни одно ни природное, не синтезированное соединение не обладает этой способностью- перекрывать все pathways, только куркума.
Ну, а где хорошая новость, -как раз в упомянутой выше работе. Это не научное исследование, а обзор, где суммируют результаты научных исследований, в частности результаты, что очень важно, законченных клинических испытаний на людях. Многие клинические испытания еще продолжаются, но вот то, что уже сделано ясно демонстрирует, что прием куркумы, в обозначенных количествах, совершенно безопасен и даже при не решенной проблеме ее низкой усвояемости, наблюдается выраженное позитивное воздействие на многие формы рака, особенно рака прямой кишки и толстого кишечника. В последнем случае, такое воздействие наблюдается даже для случаев, когда раковая опухоль перестает реагировать на химиотерапию.
Ниже, приведена таблица из упомянутой выше работы, не только та, что касается рака, там приведены данные по воздействию куркумы и на другие дегенеративные заболевания.
Table I
Completed Clinical Trials with Curcumin
Disease | Pts (#) | Dosage; duration | Outcome [reference] |
---|---|---|---|
Cancer | |||
Colorectal cancer | 15 | 0.036–0.18 g/day; 4 months | Reduced glutathione S-transferase activity (13) |
15 | 0.45–3.6 g/day; 4 months | Reduced PGE2 production (14) | |
12 | 0.45–3.6 g/day; 7 days | Reduced the levels of M1G (15) | |
5 | 1.44 g/day; 6 monthsa | Reduced the number and size of polyps without any appreciable toxicity (16) | |
44 | 2 and 4 g/day; 1 month | Reduced ACF formation in smokers (17) | |
126 | 1.08 g/day; 10–30 days | Improved body weight, reduced serum TNF-α, and induced p53 expression (18) | |
Pancreatic cancer | 20 | 1.5 g/day; 6 weeks a | Reduced the lipid peroxidation and increased GSH content in patients(19) |
25 | 8 g/day | Well-tolerated, limited absorption, and showed activity in some patients (12) | |
17 | 8 g/day; 4 weeksa | Not feasible for combination therapy (20) | |
21 | 8 g/daya | Safe and well-tolerated in patients (11) | |
Breast cancer | 14 | 6 g/day; 7 day, every 3 weeksa | Safe, well-tolerated, and efficacious (21) |
Prostate cancer | 85 | 0.1 g/day; 6 monthsa | Reduced the serum PSA content in combination with isoflavones(22) |
Multiple myeloma | 26 | 4 g/day; 6 months | Decreased paraprotein load and urinary N-telopeptide of type I collagen (23) |
29 | 2–12 g/day; 12 weeksa | Safe, bioavailable, and efficacious against multiple myeloma (24) | |
Lung cancer | 16 | 1.5 g/day; 30 daysc | Reduced the urinary excretion of mutagens in smokers (25) |
Cancer lesions | 62 | Ointment | Produced remarkable symptomatic relief in patients with external cancerous lesions (26) |
58 | 3.6 g/day, 3 monthsc | Reduced the number of micronuclei in mucosal cells and in circulating lymphocytes (27) | |
25 | 8 g/day, 3 months | Improved the precancerous lesions (28) | |
100 | 2 g/day; 7 weeksa | Well tolerated, but not efficacious (29) | |
75 | 1 g/day, 7 day | Increased vitamins C and E levels, decreased MDA and 8-OHdG contents in the serum and saliva(30) | |
Head and neck cancer | 39 | 2 tablets | Decreased IKKβ kinase activity and IL-8 levels in the saliva (31) |
Inflammatory diseases | |||
Crohn disease | 5 | 1.08 g/day, 1 month + 1.44 g/day, 2 months | Significant reductions in CDAI and inflammatory indices in patients (32) |
Ulcerative proctitis | 5 | 1.1 g/day for 1 month + 1.65 g/day for 1 month | Significant reduction in symptoms as well as inflammatory indices in patients (32) |
Ulcerative colitis | 89 | 2 g/day; 6 monthsa | Prevented relapse of disease (33) |
1 | 0.5 g/day; 2–10 months | Associated with clinical and endoscopic remission of the disease (34) | |
Inflammatory bowel disease | ex vivo | 5–20 μM; 0.5–24 h | Suppressed p38 MAPK activation, reduced IL-1β, and enhanced IL-10 levels in mucosal biopsies; suppressed MMP-3 in colonic myofibroblasts (35) |
Irritable bowel syndrome | 207 | 0.072 and 0.144 g STE/day; 8 weeksc | Produced significant reduction in the prevalence of symptoms (36) |
8 | 0.5 g in food | Increased bowel motility and activated hydrogen producing bacterial flora in the colon (37) | |
Rheumatoid arthritis | 18 | 1.2 g/day; 2 weeks | Improved joint swelling, morning stiffness, and walking time (38) |
45 | 0.5 g/day; 8 weeks | Improved the RA symptoms in patients alone and in combination with diclofenac sodium (39) | |
Osteoarthritis | 50 | 0.2 g/day; 3 months | Efficacious in the management andtreatment of osteoarthritis (40) |
100 | 1 g/day; 8 months | Efficacious in the long-term management of osteoarthritis (41) | |
Chronic anterior uveitis | 53 | 1.125 g/day; 12 weeks | Efficacy and recurrence of the disease comparable to that for corticosteroid therapy without any adverse effect (42) |
Recurrent anterior uveitis | 106 | 1.2 g/day; 12–18 months | Reduced the eye discomfort after a few weeks of treatment in more than 80% of patients (43) |
Postoperative inflammation | 46 | 1.2 g/day; 6 day | Exhibited superior anti-inflammatory property compared with phenylbutazone (44) |
Gastric ulcer | 60 | 1 g/day; 6–12 weeks | Reduced ulcer formation after 12 weeks (45) |
Peptic ulcer | 45 | 3 g/day; 4 weeks | Reduced ulcer formation (46) |
H. pylori infection | 25 | 0.06 g/day; 1 weeka | Improved dyspeptic symptoms and reduced serologic signs of gastric inflammation (47) |
36 | 0.12 g/day; 4 weeksa | Insignificant effect on H. pylori eradication (48) | |
Idiopathic orbital inflammatory pseudotumor | 8 | 1.125 g/day; 6–22 months | Patients recovered from the disease (49) |
Skin conditions | |||
Vitiligo | 10 | Twice/day; 12 weeksb | Improved the repigmentation in combination with NB-UVB (50) |
Psoriasis | 40 | 1% in gel; 4 weeks | Anti-psoriatic activity in association with suppression in PhK activity (51) |
12 | 4.5 g/day; 12 weeks | Low response rate, but well-tolerated (52) | |
Neurodegenerative diseases | |||
Dejerine-Sottas disease | 1 | 1.5 g/day; 4 months and 2.5 g/day; 8 months | Exhibited safety and efficacy (53) |
Alzheimer’s disease | 33 | 2–4 g/day; 24 weeks | Observations yet to be published (54) |
34 | 1–4 g/day; 6 m | Found safe and increased vitamin E level (55) | |
Cardiac conditions | |||
Acute coronary syndrome | 70 | 0.045, 0.09, 0.18 g/day; 2 months | Reduced total cholesterol and LDL cholesterol, and increased HDL cholesterol and triglyceride content in patients (56) |
Atherosclerosis | 10 | 0.5 g/day; 7 days | Reduced serum lipid peroxides and total serum cholesterol levels, and increased HDL cholesterol (57) |
Metabolic diseases | |||
Diabetes | 1 | 5 g/day; 3 months a, c | Reduced the fasting blood sugar from 140 to 70 mg/dl (58) |
72 | 0.6 g/d; 8 weeks | Improved endothelial function and reduced levels of oxidative stress and inflammatory biomarkers (59) | |
14 | 6 g, 15–120 min | Increased postprandial serum insulin levels, insignificant effect on plasma glucose levels and the glycemic index (60) | |
240 | 1.5 g/day; 9 months | Participants showed a better overall function of β cells, with higher HOMA-β and adiponectin, and lower C-peptide and HOMA-IR (61) | |
Diabetic nephropathy | 40 | 1.5 g/day; 2 monthsc | Attenuated proteinuria, TGF-β, and IL-8 in overt type 2 diabetic nephropathy (62) |
Diabetic microangiopathy | 25 | 1 g/day, 4 weeks | Improved the symptoms of disease (63) |
Lupus nephritis | 24 | 500 mg/day, 3 months | Decreased proteinuria, hematuria, and systolic blood pressure in patients with relapsing or refractory lupus nephritis (64) |
Renal conditions | |||
Renal transplantation | 43 | 480–960 mg/day; 1 montha | Improved early outcomes in cadaveric renal transplantation (65) |
Viral diseases | |||
Acquired immunodeficiency syndrome | 40 | 2.5 g/day; 8 weeks | Viral load and CD4 cells count were unaffected (66) |
Others | |||
β-Thalassemia | 21 | 0.5 g/day; 12 months | Improved the oxidative stress parameters (67) |
Biliary dyskinesia | 76 | Extract; 3 weeksc | Relieved pain due to biliary dyskinesia (68) |
Gallbladder contraction | 12 | 0.02 g, 0.5–2 h | Reduced the gallbladder volume (69) |
Recurrent respiratory tract infections | 10 | 3 g/day; 4 weeks a | Reduced the infections and produced beneficial immunomodulatory effects (70) |
Cholecystitis | 67 | 0.1–0.25 g/day; 3 monthsa | Relieved the patients from disease (10) |
Hepatoprotection | 528 | 1 g/day; 6 months a, c | Prevented ATT-associated hepatotoxicity (71) |
Chronic arsenic exposure | 286 | 1 g/day; 3 months a | Exhibited activities against As-induced genotoxicity (72) |
Alcohol intoxication | 7 | 0.03 g, single dose | Inhibited alcohol intoxication (73) |
Chronic bacterial prostatitis | 143 | 0.2 g/day; 2 weeksa | Enhanced the efficacy of prulifloxacin in combination with other phytochemicals (74) |
И какой сухой остаток всего этого. Очень простой. Независимо от вида и стадии рака куркуму можно и нужно включать в свой ежедневный рацион.
8-OHdG 8-hydroxydeoxyguanosine, ACF aberrant crypt foci, As arsenic, ATT antituberculosis treatment, CDAI Crohn disease activity index, CD4 cluster of differentiation 4, GSH glutathione, HDL high-density lipoprotein, H. pylori Helicobacter pylori, HOMA homeostasis model assessment, IKK IκB kinase, ILinterleukin, IR insulin resistance, LDL low-density lipoprotein, M1G pyrimido[1,2-a]purin-10(3H)-one, MAPK mitogen-activated protein kinase, MDA malondialdehyde, MMP-3 matrix metalloproteinase-3, NB-UVB narrowband UVB, PGE2 prostaglandin E2, PhK phosphorylase kinase, PSA prostate-specific antigen, RA rheumatoid arthritis, STE standard turmeric extract, TGF-β transforming growth factor beta, TNF-αtumor necrosis factor-α
aCombination study
bStudy with curcumin analogue